8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
West Pharmaceutical raises 2026 guidance after strong second-quarter results
Filed with the SEC on · Summarized by InvestorsBot
West Pharmaceutical reported second-quarter 2026 net sales of $872.3 million, up 13.8% year over year, while adjusted diluted EPS rose 28.8% to $2.37; organic sales growth was 12.7%, led by biologics and high-value products. The company raised its full-year sales guidance to $3.345 billion-$3.380 billion and adjusted EPS guidance to $8.85-$9.05, repurchased $454.3 million of shares during the first half, and declared a third-quarter dividend of $0.22 per share.